Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × Biological Assay × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm, Residual 1 Lymphoproliferative Disorders 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Carboplatin 295 Cisplatin 218 Radiotherapy 177 Paclitaxel 174 Pemetrexed 165 Docetaxel 156 Gemcitabine 139 pembrolizumab 126 Erlotinib Hydrochloride 98 Etoposide 89 Magnetic Resonance Spectroscopy 83 Bevacizumab 75 Specimen Handling 67 durvalumab 64 Radiosurgery 63 Nivolumab 63 Vinorelbine 50 Drug Therapy 46 osimertinib 45 Gefitinib 42 Irinotecan 37 Biopsy 36 Topotecan 35 Radiation 35 Cyclophosphamide 35 atezolizumab 34 Standard of Care 33 Cetuximab 31 Blood Specimen Collection 30 Immunoglobulin G 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06716580 2025-12-10

EQUAL

Dana-Farber Cancer Institute

Phase NA Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡